Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Skipping the co-expression problem: the new 2A "CHYSEL" technology.

Pablo de Felipe1

  • 1Centre for Biomolecular Sciences, School of Biology, Biomolecular Sciences Building, University of St, Andrews, North Haugh, St, Andrews KY16 9ST, Scotland, UK. pdf@st-andrews.ac.uk.

Genetic Vaccines and Therapy
|September 15, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stereotypical thinking in the historiography of science and religion: creation and reception history of Reijer Hooykaas's <i>Religion and the Rise of Modern Science</i>.

Annals of science·2026
Same author

The Coming of Age of Gene Therapy for the Treatment of Human Diseases: A Regulatory Perspective.

Human gene therapy·2025
Same author

'2A-Like' Signal Sequences Mediating Translational Recoding: A Novel Form of Dual Protein Targeting.

Traffic (Copenhagen, Denmark)·2016
Same author

Lost in translation: The biogenesis of non-LTR retrotransposon proteins.

Mobile genetic elements·2014
Same author

The committee for advanced therapies' of the European Medicines Agency reflection paper on management of clinical risks deriving from insertional mutagenesis.

Human gene therapy. Clinical development·2013
Same author

APE-type non-LTR retrotransposons of multicellular organisms encode virus-like 2A oligopeptide sequences, which mediate translational recoding during protein synthesis.

Molecular biology and evolution·2013

Researchers can now co-express multiple genes using the foot-and-mouth disease virus 2A peptide. This method simplifies gene therapy for complex diseases by enabling coordinated transgene expression from a single vector.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Genomics

Background:

  • Genomic research advances understanding of multi-gene diseases, necessitating effective gene therapy strategies.
  • Co-expressing multiple transgenes is crucial for gene therapy but faces challenges with current methods like internal ribosomal entry sites (IRESs).
  • Large IRES sizes and imbalanced expression hinder efficient multi-gene therapy approaches.

Discussion:

  • The foot-and-mouth disease virus (FMDV) 2A peptide offers a viral strategy for polyprotein expression, simplifying multi-gene co-expression.
  • The 18-amino acid FMDV 2A peptide acts as a linker, facilitating autonomous, self-processing of polyproteins during translation.
  • This 2A peptide system overcomes limitations of traditional methods, enabling efficient and balanced co-expression of multiple transgenes.

Related Experiment Videos

Key Insights:

  • The FMDV 2A peptide enables autonomous, intra-ribosomal self-processing of polyproteins, eliminating the need for proteases.
  • This technology allows for the co-expression of up to four proteins from a single retroviral vector.
  • The 2A peptide is compatible with various sub-cellular targeting signals, enhancing its versatility.

Outlook:

  • The FMDV 2A peptide is a valuable tool for co-expressing multiple proteins, crucial for gene therapy of complex genetic disorders.
  • This technology supports research involving heteromultimeric proteins, complex biochemical pathways, and synergistic gene functions.
  • Future applications include advancing gene therapy for multi-gene diseases and engineering complex biological systems.